Acetazolamide-Induced Sickle Cell Crisis

Idiopathic Intracranial Hypertension: An Unusual Cause of Headache in a Patient With Sickle Cell Disease

“…11 The optimal dose of acetazolamide in IIH is a total daily dose (TDD) of 2 to 4 g. 12 Consequences of CAI use include volume depletion and metabolic acidosis, which have been linked to an increased risk for vaso-occlusive episodes in SCD. 13 , 14 Our patient had to reduce her dose of acetazolamide due to an increase in vaso-occlusive episodes once starting the medication, resulting in a TDD lower than the 2-4 g target. 12 While off-label use of alternative CAIs such as topiramate and methazolamide in IIH is common, evidence for their safety and efficacy in the SCD population is lacking.…”

“… 12 While off-label use of alternative CAIs such as topiramate and methazolamide in IIH is common, evidence for their safety and efficacy in the SCD population is lacking. 3 , 13 , 14 …”

“…12 While off-label use of alternative CAIs such as topiramate and methazolamide in IIH is common, evidence for their safety and efficacy in the SCD population is lacking. 3,13,14 While IIH is an uncommon diagnosis in those with SCD, all previously reported cases of IIH in SCD adults occurred in those with comorbid obesity. The diagnosis of IIH in a nonobese SCD adult taking hydroxyurea raises the possibility that SCD or associated hydroxyurea use may be risk factors for IIH.…”